Merck is acquiring Terns Pharma for $6.7 billion to strengthen its cancer drug pipeline, aiming to reduce reliance on its blockbuster Keytr...

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...

Moderna and Merck said on Tuesday their ⁠experimental personalized vaccine continued to cut the risk of death or recurrence of the most dea...

Merck & Co revealed job and cost reductions to save $3 billion annually. This decision followed lower second-quarter results. Weak demand f...

Merck is close to buying Verona Pharma, a biotech firm specializing in lung diseases. The deal is valued at around $10 billion. Merck aims ...

Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a high...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...

Chinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In Ind...

The deal adds promising drug candidates to Merck's oncology portfolio, as its bestselling cancer therapy Keytruda will see its patent expir...

Data revealed that using Merck's immunotherapy drug in combination with high-risk patients decreased their risk of dying.

Novel cancer drugs often come with six-figure price tags, so success could be lucrative. Numerous companies are chasing a cancer vaccine. O...

DCGI gave MSD permission to market Keytruda in June 2016, according to minutes of the regulator’s Subject Expert Committee on oncology and ...

The accelerated regulatory clearances cut the time lines for introductions of the two big brands which may be expected to be introduced by ...

"I see the progress made by the Modi administration towards not only ensuring that India can meet the needs of its people in healthcare, bu...

The Delhi High Court decision on its anti-diabetes drug Januvia is among the factors encouraging Merck to invest in India, global CEO Kenne...

Merck’s competitors have lined up their own immunotherapy drugs. They include Bristol Myers Squibb (BMS), Roche & Novartis & several smalle...